EGFR and breast carcinoma: Therefore, to further corroborate the cytotoxicity profile of the compounds, we assessed the mammosphere‐forming capability of breast cancer cells treated with doxorubicin in the absence or presence of the selected compounds—1c, 1e, 1g, 1h, 1j, and 1k as potential EGFR inhibitors, based on their low IC50 values in MDA‐MB‐231 and MDA‐MB‐468 breast cancer cells.